Completed
Naltrexone Treatment for Alcoholism: Predicting Outcome
Led by Johns Hopkins University · Updated on 2010-05-14
192
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
J
Johns Hopkins University
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or a placebo. This part of the study will last 12 weeks, with regular measurements of drinking level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of the study.
CONDITIONS
Official Title
Naltrexone Treatment for Alcoholism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meets criteria for alcohol dependence.
- Committed to alcohol abstinence as a treatment goal.
- Individuals will be required to identify two family members or close friends who are knowledgeable about their location, drinking behavior, and psychosocial status.
You will not qualify if you...
- Meets criteria for any other psychoactive substance use disorder (excluding nicotine and caffeine).
- Meets criteria for a major psychiatric disorder and are in need of or currently undergoing pharmacotherapy.
- Females who are pregnant, lactating, or not using a reliable method of contraception.
- Currently experiencing a serious medical condition that would place them at risk or interfere with study participation.
- Experiencing acute hepatitis or liver failure or whose liver function test is more than 3 times normal.
- Have a history of severe allergies, multiple adverse drug reactions or known allergy to naltrexone.
- Vocabulary below the 5th grade reading level.
- Abnormal MRI scan.
- HIV infection due to the neurological sequelae.
- Significant central nervous system diseases.
- Seizure disorder or history of closed head trauma.
- Neuroendocrine disorders.
- Treatment with opiates within the last six months.
Trial Site Locations
Total: 1 location
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21205
Status Unknown
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
RANDOMIZED
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here